Protalix Fabry Disease Treatment Recommended for Approval by EMA Committee
MT Newswires Live
Jan 30
Protalix BioTherapeutics and Chiesi Global Rare Diseases said Friday that Elfabrio, an enzyme replacement therapy to treat Fabry disease, has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Protalix will be eligible to receive a regulatory milestone payment of $25 million if the treatment is approved by the European Commission, the companies said.
Protalix shares were more than 7% higher in recent trading.
Price: 2.26, Change: +0.18, Percent Change: +8.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.